KALV实时信号 | 通过Getagraph.com最大化利润

购买 107525 min ago

@ $14.93

发出时间: 15 Feb 2024 @ 03:24

回报率: -27.77%

上一信号: Feb 15 - 01:07

上一信号: 出售

回报率: -1.62 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs...

Stats
今日成交量	241 417
平均成交量	817 554
市值	454.79M
EPS	$0 ( 2024-03-14 )
下一个收益日期	( $-0.690 ) 2024-07-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.46
ATR14	$0.0170 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Fairey William	Buy	17 000	Stock Option (Right to Buy)
2024-04-18	Fairey William	Buy	0
2024-03-06	Palleiko Benjamin L	Buy	250 000	Restricted Stock Unit
2024-02-20	Venrock Healthcare Capital Partners Iii, L.p.	Buy	655 738	Pre-Funded Warrants (Right to Buy)
2024-02-17	Feener Edward P.	Buy	18 788	Common Stock

INSIDER POWER
66.06
Last 98 transactions
Buy: 3 056 025 \| Sell: 628 012

音量相关性

長: 0.33 (neutral)

短: 0.30 (neutral)

Signal:(58.845) Neutral

Kalvista Pharmaceuticals 相关性

10 最正相关
ACLS	0.953
BWMN	0.951
NVCN	0.949
NVAC	0.947
CRUS	0.947
TETC	0.947
XFIN	0.946
FOCS	0.944
JMAC	0.943
GENQ	0.941

10 最负相关
NAKD	-0.955
AMGN	-0.935
THMA	-0.932
BHTG	-0.93
LGMK	-0.926
PCSA	-0.925
AHPI	-0.924
TRIT	-0.918
CREG	-0.911
PLIN	-0.907

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kalvista Pharmaceuticals 相关性 - 货币/商品

0.17
( neutral )

0.13
( neutral )

0.00
( neutral )

0.03
( neutral )

0.50
( weak )

-0.12
( neutral )

Kalvista Pharmaceuticals 财务报表

Annual	2023
营收:	$0
毛利润:	$-802 000 (0.00 %)
EPS:	$-2.68

FY	2023
营收:	$0
毛利润:	$-802 000 (0.00 %)
EPS:	$-2.68

FY	2022
营收:	$0
毛利润:	$-743 000 (0.00 %)
EPS:	$-2.80

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.42

Financial Reports:

No articles found.

Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.